Emcure Pharmaceuticals

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA to AA- by 2 agencies.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 23% and profit rose 36% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 78% of the company, about the same as in Jun 2025.
• ValuationNormal for this stockThe share trades at 34.5 times its yearly earnings (P/E), cheaper than 60% of the time in the last 2 years. Its usual P/E is about 35.

Emcure Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)34.5 against a typical 34.6: cheaper than most peers (1st = cheapest).110th of 220
• Sales growth+22.8% against a typical +15.6% from a year earlier.71st of 197
• Profit growth+35.8% against a typical +18.9% from a year earlier.64th of 160
• Share price, 3 months−1.9% against a typical −0.5%.108th of 200
• Size₹ 33,863.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).18th of 199

Exchange filings and their impact on the company.

• 12 Oct 2026Amalgamation/MergerLow impactPositivePrice +1.9% that day
  Emcure to merge two wholly owned subsidiaries into itself to simplify structure with no change to consolidated business.

  Emcure Pharmaceuticals board on October 12, 2026 approved merger of its wholly owned subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals into itself, subject to regulatory approvals. As both are 100% owned, the merger does not add new business or change consolidated sales and profits. It simplifies the group structure and should save small duplicate compliance and admin costs over the next year.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Satish Ramanlal Mehta

Chief Executive Officer, Managing Director, Executive Director

Tajuddin Sabir Shaikh

Chief Financial Officer

Deepak Gondaliya

President - Technical Operations

Sanjay Rajanikant Mehta

President - Emerging Markets

Vikas Thapar

President of Corporate Development, Strategy and Finance

Mukund Keshao Gurjar

Chief Scientific Officer, Whole Time Director

Amruta Amit Yangalwar

Compliance Officer, Company Secretary

Samit Satish Mehta

Whole Time Director